FOLH1 and prostate carcinoma: The Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) classification, proposed in 2018, consists of a standardized reporting framework to organize PSMA-ligand PET/CT or PET/MRI findings into specific categories to increase diagnostic certainty in the interpretation of PSMA-targeted PET imaging and endorse the exchange of information among physicians and institutions.